Maria Wołyniak

Ms. Maria Wołyniak

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2025 in Science Advances
Verified
Journal Article
Open access
MWMaciej Winiarski
Maciej Winiarski
AMAnna Madecka
Anna Madecka
AYAnjaly Yadav
Anjaly Yadav
JBJoanna Borowska
Joanna Borowska
MWMaria Wołyniak
Maria Wołyniak
EKEwelina Knapska
Ewelina Knapska
Being part of a social structure offers chances for social learning vital for survival and reproduction. Nevertheless, studying the neural mechanisms of social learning under laboratory conditions remains challenging. To investigate the impact of socially transmitted information about rewards on individual behavior, we used Eco-HAB, an automated system monitoring the voluntary behavior of group-housed mice under seminaturalistic conditions. In these settings, male mice spontaneously form social networks, with individuals occupying diverse positions. We show that a rewarded group member’s scent affects the ability of conspecifics to search for rewards in familiar and novel environments. The scent’s impact depends on the animal’s social position. Furthermore, disruption of neuronal plasticity in the prelimbic cortex (PL) disrupts the social networks and animals’ interest in social information related to rewards; only the latter is blocked by the acute PL inhibition. This experimental design represents a cutting-edge approach to studying the brain mechanisms of social learning.

10 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MWMaria Wołyniak
Maria Wołyniak
Ewa Małecka-WojcieskoEwa Małecka-Wojciesko
Ewa Małecka-Wojciesko
Marta ZielinskaMarta Zielinska
Marta Zielinska
AFAdam Fabisiak
Adam Fabisiak
Inflammatory bowel diseases (IBD) refer to a group of gastrointestinal (GI) disorders with complex pathogenesis characterized by chronic intestinal inflammation with a variety of symptoms. Cannabinoid and nociceptin opioid receptors (NOPs) and their ligands are widely distributed in the GI tract. The nociceptin opioid receptor is a newly discovered member of the opioid receptor family with unique characteristics. Both cannabinoid and NOP systems exhibit antinociceptive and anti-inflammatory activity and contribute to maintaining proper motility, secretion and absorption in the GI tract. Furthermore, they influence high and low voltage calcium channels, which play a crucial role in the processing of pain, and share at least two kinases mediating their action. Among them there is NF-κB, a key factor in the regulation of inflammatory processes. Therefore, based on functional similarities between cannabinoid and nociceptin receptors and the anti-inflammatory effects exerted by their ligands, there is a high likelihood that there is an interaction between cannabinoid receptors 1 and 2 and the nociceptin receptor in colitis. In this review, we discuss potential overlaps between these two systems on a molecular and functional level in intestinal inflammation to create the basis for novel treatments of IBD.

26 January 2026 in Pharmacological Reports
Verified
Journal Article
Open access
PDF file
ZMZofia Misztal
Zofia Misztal
MWMaria Wołyniak
Maria Wołyniak
Ewa Małecka-WojcieskoEwa Małecka-Wojciesko
Ewa Małecka-Wojciesko
AFAdam Fabisiak
Adam Fabisiak
Background: Inflammatory bowel diseases (IBD) are often associated with intestinal fibrosis. There is increased interest in new methods for managing intestinal fibrosis, among which the endocannabinoid system (ECS) is an interesting therapeutic target. The primary purpose of the study was to evaluate the effect of CB1/2 agonist, WIN 55,212-2 (WIN) on expression of fibrosis regulatory proteins: alpha smooth muscle Actin 2 (ACTA2), Collagen I (COLIA1), Fibronectin 1 (FN1) and SMAD family member 3 (SMAD3) in a mice model of dextran sulfate sodium (DSS)-induced intestinal fibrosis. Methods: Chronic intestinal fibrosis was induced by oral administration of 1.5% DSS in rotation with tap water for 3 weeks in three cycles. WIN was administered intraperitoneally, once daily starting from day 10th and continued every other day until day 77th. The expression of genes encoding ACTA2, COL1A1, FN1, SMAD3, Col1a1, Fn1 both in mouse and human colon, was assessed with real-time PCR. Results: We found lower relative expression of genes encoding fibrosis regulatory proteins in colonic mucosa of mice treated with WIN than in inflamed mice: ACTA2 (–51%), COL1A1 (–44%), FN1 (–60%), and SMAD3 (–22%). Human colonic mucosal patients with UC showed higher expression of COL1A1 (+ 57%) and SMAD3 (+ 34%) compared to healthy controls. Conclusions: Our results show that regulation of ECS activity may play a role in the inhibition of intestinal fibrosis in IBD and appears as a potential therapeutic target in patients at high risk of developing strictures.

Verified
Journal Article
Open access
PDF file
GSGrzegorz Stępień
Grzegorz Stępień
KBKatarzyna Boguszewska-Byczkiewicz
Katarzyna Boguszewska-Byczkiewicz
MWMaria Wołyniak
Maria Wołyniak
MRMonika Ryś-Bednarska
Monika Ryś-Bednarska
TWThomas Wow
Thomas Wow
AKAgnieszka Kołacińska-Wow
Agnieszka Kołacińska-Wow
Background/Objectives: Triple-negative breast cancer (TNBC) is an aggressive subtype in which neoadjuvant chemotherapy plays an important role in initial treatment. Pathological complete response (pCR) following neoadjuvant therapy can serve as a surrogate marker for long-term survival. Our study aimed to evaluate the value of the Pan-Immune-Inflammation Value (PIV), Neutrophil-to-Lymphocyte Ratio (NLR), and Platelet-to-Lymphocyte Ratio (PLR), measured at multiple time points, in predicting pCR. Methods: We retrospectively included 89 patients with non-metastatic TNBC treated with neoadjuvant chemotherapy with or without immunotherapy, followed by surgery. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Pan-Immune-Inflammation Value (PIV) were calculated at baseline, before the second treatment cycle, and at the pragmatic pre-transition assessment before a subsequent treatment phase, when applicable. The primary endpoint was pCR, defined as ypT0N0. Multivariable logistic regression models included age, Ki-67, clinical T stage, and tumor grade. Biomarker-extended models were compared with the clinical model on identical complete-case samples. Model performance was assessed using the area under the receiver operating characteristic curve (AUC), likelihood ratio testing, calibration measures, Brier scores, and bootstrap internal validation with 2000 resamples. Results: pCR was achieved in 25 of 89 patients (28.1%). Baseline platelet counts were lower in patients with pCR than in those without pCR (median 246 × 103/µL vs. 272 × 103/µL; p = 0.021). At the pre-transition assessment, patients with pCR had lower monocyte counts (0.20 × 103/µL vs. 0.57 × 103/µL; p = 0.048) and lower PIVs (378.9 vs. 746.0; p = 0.011). Baseline PIV did not improve the clinical model. On the same 83-patient sample, adding baseline platelet count increased the apparent AUC from 0.751 to 0.807; however, the bootstrap 95% confidence interval (CI) for the AUC difference included zero (−0.003 to 0.128). On the same 75-patient sample, adding pre-transition PIV increased the apparent AUC from 0.735 to 0.798, with a bootstrap 95% confidence interval for the AUC difference of 0.005 to 0.142. The optimism-corrected AUC for the overall clinical model was 0.716, indicating lower internally validated performance than suggested by the apparent AUC. A smaller absolute increase in PIV from baseline to the pre-transition assessment was associated with pCR, but this finding was definition-dependent and remained exploratory. Conclusions: Standalone baseline markers have limited utility in predicting pCR in non-metastatic TNBC. Pre-transition PIV showed the most consistent incremental association with pCR beyond conventional clinical variables, whereas the added value of baseline platelet count was uncertain and baseline PIV provided no incremental benefit. Because of the retrospective design, limited sample size, treatment heterogeneity, and evidence of model optimism, these findings should be regarded as hypothesis-generating and require external validation.

Verified
Journal Article
Open access
PDF file
MWMaria Wołyniak
Maria Wołyniak
EZEdward Zheng
Edward Zheng
MPMateusz Polak
Mateusz Polak
STStanisław Trojanowski
Stanisław Trojanowski
Ewa Małecka-WojcieskoEwa Małecka-Wojciesko
Ewa Małecka-Wojciesko
MicroRNAs are small noncoding RNA molecules that regulate gene expression at the post-transcriptional level and play a key role in cancer development, progression, and response to therapy. Their relative stability in biological fluids and disease-associated expression patterns have positioned microRNAs as promising candidates for non-invasive cancer biomarkers. Liquid biopsy enables the detection of circulating and fluid-derived microRNAs in a range of biological materials, including blood, urine, saliva, stool, pancreatic cyst fluid, and bile, offering a minimally invasive complement to tissue-based diagnostics. This approach is particularly relevant in pancreatic ductal adenocarcinoma, a malignancy with high mortality driven largely by late diagnosis, aggressive disease course, and limited opportunities for curative treatment. This review summarizes current evidence on microRNA-based liquid biopsy approaches in this cancer, with a focus on diagnostic, prognostic, and predictive relevance. Serum and plasma remain the most extensively studied sources, while urine-based microRNA profiling has shown relatively consistent diagnostic performance across available studies, including in early-stage disease. Pancreatic cyst fluid and bile offer more lesion-proximal molecular information but are limited to selected clinical scenarios because of invasive sampling requirements. In contrast, salivary microRNA signatures show greater variability and lower reproducibility across studies. Overall, liquid biopsy based on microRNA analysis shows promise as a complementary tool for pancreatic ductal adenocarcinoma detection and risk stratification. However, substantial methodological heterogeneity and limited cross-study reproducibility currently limit clinical translation, underscoring the need for standardized workflows and prospective validation of clinically relevant microRNA panels.